Core Viewpoint - Teladoc Health's stock price increased by over 9%, reaching $9.398, following updates from several Wall Street firms on its rating and target price [1] Summary by Category Stock Performance - Teladoc Health's stock rose more than 9% to $9.398 as of the report [1] Analyst Ratings - Multiple major Wall Street firms updated their ratings for Teladoc Health, with target prices ranging from $9 to $12 [1] - Bank of America analyst Allen Lutz maintained a "Hold" rating and raised the target price from $8.5 to $9 [1]

智通财经APP获悉，周五，Teladoc Health(TDOC.US)股价走高，截至发稿，该股涨超9%，报9.398美 元。多家华尔街大行更新了Teladoc Health的评级，目标价介于9美元至12美元。其中，美银证券分析师 Allen Lutz维持持有评级，并将目标价从8.5美元上调至9美元。 ...

This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Dive Brief: Teladoc Health CFO Mala Murthy is stepping down from her role effective Nov. 21, the telehealth company said Thursday. Murthy, who has served as finance chief at the firm since 2019, is leaving Teladoc to pursue an opportunity outside the healthcare sector, according to a press release. Alongside the leadership news, Teladoc released prelimin ...

Exhibit 99.1 Teladoc Health Announces Chief Financial Officer Transition Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaf irms Full-Year 2025 Consolidated Outlook "It has been a privilege to serve as Teladoc Health's Chief Financial Officer during a pivotal time in virtual care," said Murthy. "I'm deeply grateful for the opportunity to have worked with such an exceptional, committed team." In conjunction with this leadership announcement, Teladoc Health reaffirmed its 2025 full-y ...

Provides Preliminary Third Quarter 2025 Consolidated Financial Results, Reaffirms Full-Year 2025 Consolidated OutlookNEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced that Mala Murthy will be stepping down from her role as Chief Financial Officer to pursue an opportunity outside of the healthcare industry. Ms. Murthy will continue to serve in her role until her departure on November 21, 2025 and will present on the company’s third qua ...

Core Insights - The article discusses two underperforming healthcare companies, Iovance Biotherapeutics and Teladoc Health, and evaluates their potential as contrarian investment opportunities [2][13]. Group 1: Iovance Biotherapeutics - Iovance Biotherapeutics is a small-cap biotech company known for its advanced melanoma treatment, Amtagvi, which was approved in February 2024 [3][4]. - Revenue from Amtagvi reached $109.3 million in the first half of 2025, more than tripling from the previous year [3]. - The company projects annual revenue of $250 million to $300 million, with a current market cap of $773 million [4]. - Iovance has received approval for Amtagvi in Canada and plans to expand into other countries, targeting a significant market due to the high mortality rate from melanoma in the U.S. [4][5]. - Amtagvi is also being investigated for treating other cancers, which could further enhance sales if clinical progress is made [6]. - The complexity of manufacturing and administering Amtagvi poses challenges, as it requires 34 days to prepare and can only be administered in specialized centers [6][7]. Group 2: Teladoc Health - Teladoc Health has experienced a decline in traction but maintains a large ecosystem with 102.4 million members in its integrated care segment, an 11% increase year-over-year [8]. - The company is addressing subscriber losses in its BetterHelp virtual therapy segment through acquisitions, including UpLift, which has insurance agreements covering 100 million potential patients [9][10]. - Teladoc's second-quarter revenue fell by 2% year-over-year to $631.9 million, but its established presence in telemedicine and international expansion efforts may support a recovery [11][12]. - Despite the risks, Teladoc is viewed as a more attractive investment option due to higher revenue and lower net losses compared to Iovance [13][15].

NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release third quarter 2025 results on Wednesday, October 29, 2025, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing 1-833-470-1428 for U.S. participants and using the access code # 609817. For international participants, ...

Core Viewpoint - Teladoc (TDOC) is showing potential for short-term gains as it has crossed above the 20-day moving average, indicating a bullish trend [1][4]. Technical Analysis - TDOC has reached a key level of support and has been moving higher over the past four weeks, with an increase of 13.5% [1][4]. - The 20-day simple moving average is a significant indicator for short-term traders, as it smooths out price trends and provides more signals for trend reversals compared to longer-term averages [1][2]. Earnings Estimates - The company currently holds a Zacks Rank 1 (Strong Buy), suggesting a favorable outlook for continued price increases [4]. - In the past two months, no earnings estimates for TDOC have been lowered, while one estimate has been raised, contributing to a positive consensus estimate for the current fiscal year [4][5].

Group 1 - Teladoc (TDOC) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - The stock has moved 13.5% higher over the last four weeks and is currently rated as a Zacks Rank 1 (Strong Buy) [2] - Positive earnings estimate revisions support the bullish outlook, with no estimates decreasing in the past two months and one estimate increasing, leading to a consensus estimate increase [2] Group 2 - Investors are encouraged to monitor TDOC for potential gains due to its key technical level and favorable earnings estimate revisions [3]

Core Insights - Teladoc Health, Inc. has launched a new solution as part of its Clarity monitoring platform, aimed at enhancing workplace safety in healthcare settings by addressing workplace violence [1][4][9] Group 1: New Features and Implementation - The Clarity platform now includes features for virtual intervention to combat workplace violence, initially designed for virtual patient sitting [1][2] - The new workplace safety feature will be rolled out in partnership with selected hospitals and health systems starting in Q1 2026 [2] - The functionality utilizes video and audio analysis to detect threats, sending real-time alerts to care teams for timely intervention [3][9] Group 2: Industry Context and Benefits - Workplace violence is a growing concern in hospitals, impacting staff safety and imposing financial burdens on healthcare institutions [4] - The addition of the new capability is expected to enhance the attractiveness of the Clarity platform, potentially increasing Teladoc Health's revenue as more hospitals adopt the solution [5] Group 3: Company Performance - Teladoc Health's shares have increased by 29.4% over the past six months, significantly outperforming the industry average growth of 1.2% [8]